Antibiotic Resistance: Implications for Global Health and Novel Intervention Strategies: Workshop Summary (2010)
Chapter: Appendix B: Agenda
Appendix B
Agenda
Antimicrobial Resistance: Implications for Global Health and Novel Intervention Strategies
April 6–7, 2010
Keck Building, Room 100
500 Fifth Street, NW
Washington, DC
DAY 1: APRIL 6, 2010
|
8:30–9:00: |
Registration and Continental Breakfast |
|
9:00–9:15: |
Welcoming Remarks: David A. Relman, M.D., Chair, and James M. Hughes, M.D., Vice-Chair, Forum on Microbial Threats |
|
9:15–10:00: |
Keynote Remarks: The Effects of Antibiotic and Pesticide Resistance on Public Health |
|
|
David Pimentel, Ph.D. Cornell University |
|
10:00–10:30: |
Discussion |
|
10:30–10:45: |
Break |
Session I
Where Does Resistance Come From?
Moderator: David A. Relman, M.D.
|
10:45–11:15: |
Origins of AMR—Antimicrobials as Agents of Selection and Directed Evolution |
|
|
Henry Chambers, M.D. University of California, San Francisco |
|
11:15–11:45: |
Population Mobility, Globalization, and AMR |
|
|
Douglas MacPherson, M.D., M.Sc. (CTM), FRCPC Migration Health Consultants, Inc., and McMaster University |
|
11:45–12:15: |
Antibiotics in the Environment: Natural and Anthropogenic Contributions |
|
|
Julian Davies, Ph.D. University of British Columbia |
|
12:15–12:45: |
Discussion of Session I |
|
12:45–1:30: |
Lunch |
Session II
Antimicrobial Resistance: Evolution/Ecology/Environment
Moderators: Frederick Sparling, M.D., and Lonnie King, D.V.M.
|
1:30–2:00: |
AMR in the Environment and the Evolution of Resistance |
|
|
Gerard Wright, Ph.D. McMaster University |
|
2:00–2:30: |
Antibiotic-Induced Resistance Flow |
|
|
Patrice Courvalin, M.D. Institut Pasteur |
|
2:30–3:00: |
The Contribution of Antimicrobial Use in Food Animal Production to the Emergence of Antimicrobial Resistance in Human Pathogens |
|
|
Jørgen Schlundt, Ph.D., D.V.M. World Health Organization |
|
3:00–3:30: |
Questions |
|
3:30–3:45: |
Break |
|
3:45–4:15: |
Antimicrobial Resistance in Europe: Burden and Successful Prevention and Control Initiatives |
|
|
Dominique L. Monnet, Pharm.D., Ph.D. European Centre for Disease Prevention and Control (ECDC) |
|
4:15–4:45: |
Current and Future Trends/Projections in AMR—What Does the Problem Look Like in 5, 10 Years? |
|
|
Ramanan Laxminarayan, Ph.D., M.P.H. Resources for the Future and Princeton University |
|
4:45–5:15: |
What Is Causing the Antibiotic Pipeline to Dry Up? |
|
|
Brad Spellberg, M.D. University of California, Los Angeles |
|
5:15–5:45: |
Hospital and Societal Costs of AMR Infections |
|
|
Robert Weinstein, M.D. John Stroger Hospital of Cook County |
|
5:45–6:15: |
Questions and Discussion |
DAY 2: APRIL 7, 2010
Paths Forward: Novel Therapeutic Approaches, Mitigation, Intervention
|
8:15–8:30: |
Continental Breakfast |
|
8:30–8:45: |
Summary of Day 1 and Preview of Day 2: David Relman, M.D. |
Session III
Novel Approaches for Drug Discovery, Development, and Mitigation of Resistance
Moderator: Jesse Goodman, M.D., M.P.H.
|
8:45–9:15: |
Antibiotic Scaffolds: Past, Present, and Future |
|
|
Michael Fischbach, Ph.D. University of California, San Francisco |
|
9:15–9:45: |
Radical Mechanisms Leading to Antibiotic Resistance |
|
|
James J. Collins, Ph.D. Boston University |
|
9:45–10:15: |
Novel Approaches for Drug Discovery |
|
|
Kim Lewis, Ph.D. Northeastern University |
|
10:15–10:30: |
Break |
|
10:30–11:00: |
Returning to Pathogen Specificity with Antibody Therapy |
|
|
Arturo Casadevall, M.D., Ph.D. Albert Einstein College of Medicine |
|
11:00–11:30: |
Challenges in Antimicrobial Susceptibility Testing of Clinical and Environmental Isolates |
|
|
Fred Tenover, Ph.D., D(ABMM), F(AAM), F(IDSA) Cepheid |
|
11:30–12:00: |
Clinical Management Issues, Outcomes |
|
|
Louis B. Rice, M.D. Louis Stokes Cleveland VA Medical Center |
|
12:00–12:30: |
Discussion of Session III |
|
12:30–1:15: |
Lunch |
Session IV
Think Globally, Act Regionally (and Locally): Panel Discussion on Prudent Use, Stewardship, Global Engagement, Incentives: How Do We Get from Where We Are to Where We Want to Be?
Moderators: David Heymann, M.D., and James Hughes, M.D.
|
1:15–2:15: |
Prudent Use, Stewardship, Market Incentives, and Global Engagement |
|
|
Stuart Levy, M.D., Tufts University and the Alliance for Prudent Use of Antibiotics |
|
|
Shelley Hearne, Ph.D., The Pew Charitable Trusts |
|
|
Jeffrey Levi, Ph.D., Trust for America’s Health |
|
2:15–4:30: |
Open Discussion with Panelists, Forum Members, and Audience |
|
|
Julian Davies, Ph.D., University of British Columbia Gerard Wright, Ph.D., McMaster University Jørgen Schlundt, Ph.D., D.V.M., World Health Organization Brad Spellberg, M.D., University of California, Los Angeles Ed Cox, M.D., M.P.H., Food and Drug Administration/Center for Drug Evaluation and Research |
|
4:30–5:00: |
James Hughes, M.D., and David Relman, M.D., Wrap-Up and Adjournment |
|
5:00: |
Meeting Adjourns |
